The development of antibodies against human Factor VIII (FVIII) is one of the most detrimental complications in the treatment of hemophilia A, as well as in patients with acquired hemophilia.

According to the Association of Hemophilia Centre Directors of Canada, all hemophilia A patients who have received Factor VIII infusions as well as those patients who are suspected of having acquired hemophilia A should be screened for the presence of anti-FVIII antibodies.^1,2

LIFECODES Factor VIII Antibody Screen provides the following key functionality:

• Detects low titer antibodies to human FVIII
• Fast and efficient way to screen out Bethesda negative samples
• Detects relevant non-inhibitory antibodies thought to increase FVIII clearance

¹ LIFECODES Factor VIII Antibody Screen for in vitro diagnostic use [package insert], Waukesha, WI; Gen-Probe GTI Diagnostics, Inc., 2009.
² Treatement of Hemophilia Monograph Series, Number 10”. Association of Hemophilia Centre Directors of Canada 3rd Edition 1999.

LIFECODES Factor VIII Antibody Screen product is cleared for In Vitro Diagnostic Use by the FDA.

For additional availability in other countries please contact your local sales representative or distributor.

Technical Bulletins are now available on the Downloads Tab